Business
SPEC: Clinical progress and new funding strengthen position despite ongoing losses
SPEC: Clinical progress and new funding strengthen position despite ongoing losses
About this update from Spectracure Ab
Key clinical milestones achieved, including first patient treatment in primary prostate cancer study, and SEK 54.8 million raised to support ongoing trials. Net loss widened year-over-year, but cash flow and equity position improved after the rights issue.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.